215
Participants
Start Date
March 31, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
February 28, 2015
Golimumab 50 mg
Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
Mavrilimumab 100 mg
Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
Research Site, Ciudad Autonoma Buenos Aires
Research Site, Córdoba
Research Site, San Miguel de Tucumán
Research Site, Barranquilla
Research Site, Prague
Research Site, Uherské Hradiště
Research Site, Zlín
Research Site, Montpellier
Research Site, Athens
Research Site, Heraklion
Research Site, Larissa
Research Site, Baja
Research Site, Balatonfüred
Research Site, Budapest
Research Site, Ashkelon
Research Site, Haifa
Research Site, Kfar Saba
Research Site, Petah Tikva
Research Site, Rehovot
Research Site, Mérida
Research Site, Coimbra
Research Site, Lisbon
Research Site, Viseu
Research Site, Kazan'
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Belgrade
Research Site, Niška Banja
Research Site, Bardejov
Research Site, Bratislava
Research Site, Kosice - Saca
Research Site, Barcelona
Research Site, Bilbao
Research Site, Málaga
Research Site, Birkenhead
Research Site, Cambridge
Research Site, Edinburgh
Research Site, London
Research Site, Plymouth
Lead Sponsor
MedImmune LLC
INDUSTRY